Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis

Status unconfirmed

Conditions studied: Renal Failure, Bacterial Infections, Critical Illness

In brief

The study's primary objective is to determine plasma and dialysis fluid concentrations in patients prescribed ceftazidime-avibactam as the standard treatment for their infection and requiring continuous venovenous hemodiafiltration (CVVHDF) as part of the standard treatment for acute or chronic renal failure. Secondarily, the study will evaluate the pharmacokinetics of ceftazidime-avibactam in these patients on CVVHDF. The study will also determine if the prescribed dose meets pharmacodynamic targets.

Key facts

Study ID

NCT03243864

Run by

Temple University

People needed

10

Starts

2017-03-13

Expected to finish

2020-10-21

Last updated by the study team

2019-04-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults > 18 years of age
• Patients requiring continuous renal replacement therapy (CRRT) due to acute or chronic renal failure
• documented or suspected infection requiring a prescription for ceftazidime-avibactam

You may not qualify if…

• Patients on CRRT < 24 hours
• Patients on ceftazidime-avibactam < 24 hours
• Patients unable to remain on CRRT for 32 hours continuously without clotting

Where it is running

• Temple University Hospital — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.